APA (7th ed.) Citation

Kolyadina, I. V., Ganshina, I. P., Kuzmicheva, S. V., Tekeeva, A. I., Kolokolov, J. D., Volkonskii, M. V., & Poddubnaya, I. V. (2020). Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: Theoretical background and first experience. IP Habib O.N.

Chicago Style (17th ed.) Citation

Kolyadina, Irina V., Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii, and Irina V. Poddubnaya. Prospects of Eribulin Administration for Patients with HR-positive HER2-negative Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors: Theoretical Background and First Experience. IP Habib O.N, 2020.

MLA (8th ed.) Citation

Kolyadina, Irina V., et al. Prospects of Eribulin Administration for Patients with HR-positive HER2-negative Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors: Theoretical Background and First Experience. IP Habib O.N, 2020.